|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.480 CAD | -1.33% |
|
-5.73% | +12.98% |
Company Valuation: Cardiol Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 142 | 43.96 | 71.77 | 151 | 130.4 | 167.8 | - | - |
| Change | - | -69.05% | 63.28% | 110.34% | -13.65% | 28.72% | - | - |
| Enterprise Value (EV) 1 | 142 | 43.96 | 36.84 | 120.4 | 108.9 | 152.8 | 157.6 | 167.8 |
| Change | - | -69.05% | -16.19% | 226.78% | -9.5% | 40.25% | 3.11% | 6.51% |
| P/E Ratio | -3.19x | -1.41x | -2.5x | -3.63x | -3.36x | -4.17x | -6.45x | 40.9x |
| PBR | - | - | 2.55x | 6.18x | 6.41x | 8.52x | 15.6x | - |
| PEG | - | 0x | 0.2x | -0.2x | 0.1x | 0.54x | 0.2x | -0x |
| Capitalization / Revenue | 1,803x | - | - | - | - | - | 50.5x | 4.62x |
| EV / Revenue | 1,803x | - | - | - | - | - | 47.4x | 4.62x |
| EV / EBITDA | -4.74x | -1.07x | -1.25x | -3x | -3.18x | -6.49x | -9.92x | -8.14x |
| EV / EBIT | -3.67x | -1.06x | -1.24x | -2.99x | -3.17x | -4.35x | -5.86x | 34.8x |
| EV / FCF | -6.03x | - | -1.46x | -4.8x | -4.56x | -7.53x | -33.7x | - |
| FCF Yield | -16.6% | - | -68.5% | -20.8% | -21.9% | -13.3% | -2.97% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.73 | -0.49 | -0.44 | -0.51 | -0.39 | -0.36 | -0.2325 | 0.0367 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.0788 | - | - | - | - | - | 3.321 | 36.32 |
| EBITDA 1 | -29.95 | -41.12 | -29.54 | -40.11 | -34.21 | -23.54 | -15.88 | -20.62 |
| EBIT 1 | -38.66 | -41.34 | -29.79 | -40.28 | -34.32 | -35.09 | -26.87 | 4.821 |
| Net income 1 | -31.64 | -30.93 | -28.13 | -36.68 | -33.82 | -35.21 | -30.57 | -8.68 |
| Net Debt 1 | - | - | -34.93 | -30.58 | -21.42 | -15.01 | -10.26 | - |
| Reference price 2 | 2.330 | 0.690 | 1.100 | 1.850 | 1.310 | 1.500 | 1.500 | 1.500 |
| Nbr of stocks (in thousands) | 60,954 | 63,703 | 65,247 | 81,603 | 99,514 | 111,872 | - | - |
| Announcement Date | 3/23/22 | 3/28/23 | 4/1/24 | 3/31/25 | 3/31/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.17x | - | -6.49x | - | 120M | |
| 29.71x | 5.27x | 16.33x | 1.11% | 42.96B | |
| -18.77x | 275.88x | -16.99x | -.--% | 31.73B | |
| 22.03x | 2.54x | 10.97x | -.--% | 30.22B | |
| 38.83x | 3.84x | 24.59x | -.--% | 28.94B | |
| 28.09x | 7.25x | 18.65x | 0.42% | 23.87B | |
| 27.88x | 4.48x | 20.38x | -.--% | 13.57B | |
| 22.34x | 1.93x | 8.51x | 1.19% | 12.96B | |
| -20.61x | 13.45x | -20.03x | -.--% | 12.2B | |
| Average | 13.93x | 39.33x | 6.21x | 0.34% | 21.84B | |
| Weighted average by Cap. | 18.09x | 48.82x | 9.12x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CRDL Stock
- Valuation Cardiol Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
